Yield10 Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>YB</div>
YTEN -- USA Stock  

USD 13.93  2.10  13.10%

It seems Yield10 Bioscience will continue to recover much faster as its share price surged up 76.90% today. The company current daily volatility is 10.21 percent, with a beta of 0.95 and an alpha of 0.11 over DOW. While many traders are getting carried away by overanalyzing yield10 bioscience, it is reasonable to outline Yield10 Bioscience. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a month ago
View all stories for Yield10 Bioscience | View All Stories
How risky is Yield10 Bioscience after the latest volatility rise?
Yield10 Bioscience currently holds roughly 11.79 M in cash with (9.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54. Our recommendation tool can cross-verify current analyst consensus on Yield10 Bioscience and to analyze the firm potential to grow in the current economic cycle.
Investing in Yield10 Bioscience, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Yield10 Bioscience along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Yield10 Bioscience's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Yield10 Bioscience in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Yield10 Bioscience. Your research has to be compared to or analyzed against Yield10 Bioscience's peers to derive any actionable benefits. When done correctly, Yield10 Bioscience's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Yield10 Bioscience.

How important is Yield10 Bioscience's Liquidity

Yield10 Bioscience financial leverage refers to using borrowed capital as a funding source to finance Yield10 Bioscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Yield10 Bioscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Yield10 Bioscience's total debt and its cash.

How Yield10 utilizes its cash?

To perform a cash flow analysis of Yield10 Bioscience, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Yield10 Bioscience is receiving and how much cash it distributes out in a given period. The Yield10 Bioscience cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Yield10 Bioscience Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (14.27 Million)

Yield10 Bioscience Correlation with Peers

Investors in Yield10 can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Yield10 Bioscience. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Yield10 Bioscience and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Yield10 is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Yield10 for more details

Yield10 Bioscience exotic insider transaction detected

Legal trades by Yield10 Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Yield10 insider trading alert for general transaction of common stock by Kristi Snell, VP Research & CSO, on 16th of February 2021. This event was filed by Yield10 Bioscience Inc with SEC on 2021-02-16. Statement of changes in beneficial ownership - SEC Form 4. Kristi Snell currently serves as chief science officer, vice president - research of Yield10 Bioscience [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Yield10 Bioscience valued adequately by the market?

Yield10 Bioscience is moderately volatile given 1 month investment horizon. Yield10 Bioscience shows Sharpe Ratio of 0.16, which attests that the company had 0.16% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.64% are justified by taking the suggested risk. Use Yield10 Bioscience Mean Deviation of 2.47, downside deviation of 3.22, and Market Risk Adjusted Performance of 0.233 to evaluate company specific risk that cannot be diversified away.
ICL
FMC
YARIY
NTR
MOS
ICL
0.880.920.960.94
ICL
FMC
0.880.890.930.84
FMC
YARIY
0.920.890.880.85
YARIY
NTR
0.960.930.880.92
NTR
MOS
0.940.840.850.92
MOS
ICL
FMC
YARIY
NTR
MOS
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Can Yield10 Bioscience build up on the latest rise?

Latest downside deviation is at 3.22. Yield10 Bioscience shows above-average downside volatility for the selected time horizon. We advise investors to inspect Yield10 Bioscience further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Yield10 Bioscience future alpha.

Our Takeaway on Yield10 Bioscience Investment

Whereas many other companies under the agricultural inputs industry are still a bit expensive, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. All things considered, as of the 16th of January 2021, our research shows that Yield10 Bioscience is a rather moderately volatile investment opportunity with a high chance of bankruptcy in the next two years. From a slightly different view, the entity currently appears to be fairly valued. Our concluding 30 days buy-hold-sell advice on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com